Coronavirus Vaccine: The US government has selected Moderna Inc’s experimental vaccine for coronavirus as one of the first to enter large-scale human trials.
Coronavirus Vaccine news: A study on Moderna Inc’s experimental vaccine for COVID-19 found it “safe” and showed high levels of virus-killing antibodies in all volunteers who were part of the study, reported Reuters. In an ongoing early-stage study, it was found that all the 45 volunteers who got two doses of Moderna Inc’s experimental vaccine for coronavirus had high levels of virus-killing antibodies that exceeded the average levels seen in people who had recovered from COVID-19, reported Reuters, citing US researchers.
According to the research paper published in the New England Journal of Medicine, there was no serious side effect, but over 50% of volunteers reported mild or moderate reactions like fatigue, headache, chills, muscle aches or pain at the injection site, reported Reuters.
- COVID-19 vaccine impact study: Antibodies significantly higher after 7 days among seropositive people
- India’s manufacturing base is playing a critical role in closing the gap between rich and poor countries: Dr Yasmin Ali Haque, UNICEF Representative
- Covid-19 vaccination drive India update: Centre urges states to utilise 100% capacities of private hospitals
These symptoms were likely to be found in volunteers after the second dose and those who got the highest dose, the paper said.
The Massachusetts-based biotech firm, Moderna Inc, started human testing of COVID-19 vaccine on March 16, just 66 days after the genetic sequence of the coronavirus was released.
WATCH VIDEO | Indian Railways unveils world’s 1st safer train coaches for post Covid-19 travel; top features!
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, whose researchers developed Moderna’s vaccine candidate, said, it’s a piece of “good news.”
Fauci said the study found no serious adverse impact on volunteers and the vaccine produced “reasonably high” levels of virus-killing or neutralising antibodies. “If your vaccine can induce a response comparable with natural infection, that’s a winner,” Reuters reported Fauci as saying.
The Trump-government in the US is backing Moderna’s vaccine with nearly half a billion dollars, reported Reuters. It has also selected it as one of the first to enter large-scale human trials. If Moderna manages to come up with a successful vaccine, it could be a turning point for the biotech firm, which has never had a licensed product, Reuters report said.